PURPOSE: To develop a pH-sensitive dexamethasone (Dex)-containing N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate with well-defined structure for the improved treatment of rheumatoid arthritis (RA). METHODS: A new pH-sensitive Dex-containing monomer (MA-Gly-Gly-NHN=Dex) was synthesized and copolymerized with HPMA using reversible addition-fragmentation transfer (RAFT) polymerization. The structure of the resulting HPMA copolymer-Dex conjugate (P-Dex) was analyzed and its therapeutic efficacy was evaluated on adjuvant-induced arthritis (AIA) rats. RESULTS: P-Dex was synthesized with controllable molecular weight and polydispersity index (PDI). The Dex content can be controlled by the feed-in ratio of MA-Gly-Gly-NHN=Dex. The P-Dex used for in vitro and in vivo evaluation has a average molecular weight (M (w)) of 34 kDa and a PDI of 1.34. The in vitro drug-release studies showed that the Dex release from the conjugate was triggered by low pH. Clinical measurements, endpoint bone mineral density (BMD) test and histology grading from the in vivo evaluation all suggest that newly synthesized P-Dex has strong and long-lasting anti-inflammatory and joint protection effects. CONCLUSIONS: A HPMA copolymer-dexamethasone conjugate with a well-defined structure has been synthesized and proved to be an effective anti-arthritis therapy. It may have a unique clinical application in the treatment of rheumatoid arthritis.
class="abstract_title">PURPOSE: To develoclass="Chemical">p a class="Chemical">pH-sensitive class="Chemical">pan class="Chemical">dexamethasone (Dex)-containing N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate with well-defined structure for the improved treatment of rheumatoid arthritis (RA). METHODS: A new pH-sensitive Dex-containing monomer (MA-Gly-Gly-NHN=Dex) was synthesized and copolymerized with HPMA using reversible addition-fragmentation transfer (RAFT) polymerization. The structure of the resulting HPMA copolymer-Dex conjugate (P-Dex) was analyzed and its therapeutic efficacy was evaluated on adjuvant-induced arthritis (AIA) rats. RESULTS:P-Dex was synthesized with controllable molecular weight and polydispersity index (PDI). The Dex content can be controlled by the feed-in ratio of MA-Gly-Gly-NHN=Dex. The P-Dex used for in vitro and in vivo evaluation has a average molecular weight (M (w)) of 34 kDa and a PDI of 1.34. The in vitro drug-release studies showed that the Dex release from the conjugate was triggered by low pH. Clinical measurements, endpoint bone mineral density (BMD) test and histology grading from the in vivo evaluation all suggest that newly synthesized P-Dex has strong and long-lasting anti-inflammatory and joint protection effects. CONCLUSIONS: A HPMA copolymer-dexamethasone conjugate with a well-defined structure has been synthesized and proved to be an effective anti-arthritis therapy. It may have a unique clinical application in the treatment of rheumatoid arthritis.
Authors: O C Boerman; W J Oyen; G Storm; M L Corvo; L van Bloois; J W van der Meer; F H Corstens Journal: Ann Rheum Dis Date: 1997-06 Impact factor: 19.103
Authors: R C Lawrence; C G Helmick; F C Arnett; R A Deyo; D T Felson; E H Giannini; S P Heyse; R Hirsch; M C Hochberg; G G Hunder; M H Liang; S R Pillemer; V D Steen; F Wolfe Journal: Arthritis Rheum Date: 1998-05
Authors: C F van Dijke; C G Peterfy; R C Brasch; P Lang; T P Roberts; D Shames; J B Kneeland; Y Lu; J S Mann; S D Kapila; H K Genant Journal: Magn Reson Imaging Date: 1999-02 Impact factor: 2.546
Authors: Xin Wei; Fei Li; Gang Zhao; Yashpal Singh Chhonker; Christine Averill; Josselyn Galdamez; P Edward Purdue; Xiaoyan Wang; Edward V Fehringer; Kevin L Garvin; Steven R Goldring; Yazen Alnouti; Dong Wang Journal: Mol Pharm Date: 2017-04-05 Impact factor: 4.939
Authors: Zhenshan Jia; Gang Zhao; Xin Wei; Dexuan Kong; Yuanyuan Sun; You Zhou; Subodh M Lele; Edward V Fehringer; Kevin L Garvin; Steven R Goldring; Dong Wang Journal: J Control Release Date: 2020-05-20 Impact factor: 9.776
Authors: Ke Ren; Anand Dusad; Fang Yuan; Hongjiang Yuan; P Edward Purdue; Edward V Fehringer; Kevin L Garvin; Steven R Goldring; Dong Wang Journal: J Control Release Date: 2013-12-08 Impact factor: 9.776
Authors: Lingdong Quan; Yijia Zhang; Anand Dusad; Ke Ren; P Edward Purdue; Steven R Goldring; Dong Wang Journal: Pharm Res Date: 2015-08-19 Impact factor: 4.200